Synthesis and cardiotonic activity of novel pyrimidine derivatives: Crystallographic and quantum chemical studies

被引:26
作者
Dorigo, P
Fraccarollo, D
Santostasi, G
Maragno, I
Floreani, M
Borea, PA
Mosti, L
Sansebastiano, L
Fossa, P
Orsini, F
Benetollo, F
Bombieri, G
机构
[1] UNIV FERRARA, IST FARMACOL, I-44100 FERRARA, ITALY
[2] UNIV GENOA, IST SCI FARMACEUT, I-16132 GENOA, ITALY
[3] UNIV MILAN, DIPARTIMENTO CHIM ORGAN & IND, I-20188 MILAN, ITALY
[4] CNR, ICTIMA, I-35100 PADUA, ITALY
[5] UNIV MILAN, IST CHIM FARMACEUT, I-20131 MILAN, ITALY
关键词
D O I
10.1021/jm9508649
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
The synthesis of ethyl or methyl 4-substituted or unsubstituted 2-(dimethylamino)-5-pyrimidinecarboxylates 10-20, which is mainly carried out by reaction of ethyl or methyl 2-[(dimethylamino)methylene]-3-oxoalkanoates with 1,1-dimethylguanidine, is described, The above esters were hydrolyzed to the relative carboxylic acids 21-30, which were decarboxylated to the corresponding 2,4-disubstituted pyrimidines 31-40. All the new synthesized pyrimidines were evaluated in spontaneously beating and electrically driven atria from reserpine-treated guinea pigs, Their effects were compared to those induced by milrinone in both atria preparations, Compound 28 (4-benzyl-2-(dimethylamino)-5-pyrimidinecarboxylic acid) was the most effective positive inotropic agent, while the corresponding methyl ester 17 reduced both the contractile force and the frequency of guinea pig atria. An antagonism toward the negative influence exerted by endogenous adenosine on the heart seems to be involved in the contractile activity of compound 28. By contrast, compound 17 might be partial agonist at the purinergic inhibitory (A1) receptor. X-ray-analysis carried out on 17 and 28 and molecular modeling investigations extended also to related derivatives allowed a possible rationalization between structure and inotropic activity for this series of compounds.
引用
收藏
页码:3671 / 3683
页数:13
相关论文
共 55 条
[11]  
DORIGO P, 1986, BRIT J PHARMACOL, V87, P623, DOI 10.1111/j.1476-5381.1986.tb14578.x
[12]  
DORIGO P, 1994, FARMACO, V49, P19
[13]   ANTAGONISM TOWARDS ENDOGENOUS ADENOSINE AND INHIBITION OF CGI-PDE IN THE CARDIAC EFFECTS OF AMRINONE, MILRINONE AND RELATED ANALOGS [J].
DORIGO, P ;
GAION, RM ;
BELLUCO, P ;
BOREA, PA ;
GUERRA, L ;
MOSTI, L ;
FLOREANI, M ;
CARPENEDO, F .
GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1992, 23 (03) :535-541
[14]  
EARL CQ, 1986, J CARDIOVASC PHARM, V8, P864
[15]  
ENDOH M, 1986, CIRCULATION, V73, P117
[17]  
ENDOH M, 1983, PHYSL PHARM ADENOSIN, P127
[18]   THE RELATIONSHIP OF THE SYMPATHETIC NERVOUS-SYSTEM AND THE RENIN-ANGIOTENSIN SYSTEM IN CONGESTIVE HEART-FAILURE [J].
FRANCIS, GS .
AMERICAN HEART JOURNAL, 1989, 118 (03) :642-648
[19]  
IJZERMAN AP, 1995, ADENOSINE AND ADENINE NUCLEOTIDES: FROM MOLECULAR BIOLOGY TO INTEGRATIVE PHYSIOLOGY, P27
[20]  
*IND U, 527 IND U